The clinical utility of genomic profiling was demonstrated in patients with advanced gastrointestinal (GI) cancers whose access to targeted therapies based on tissue-based assay findings was similar to those with non-GI cancers.
Access to targeted therapies was similar for patients with gastrointestinal (GI) cancers and non-GI cancers who underwent genomic profile testing, according to findings published recently in Targeted Oncology.
With recent advancements in precision oncology enabling targeted therapy selection for several cancers via comprehensive genomic profiling (CGP), researchers note that CGP utility for advanced GI cancers, which are associated with a poor prognosis, remains unclear because of common nondruggable alterations and rapid disease progression that prevent a sufficient time period to seek targets.
“The median survival time of patients with advanced gastric, pancreatic, and biliary cancers is around 1 year even with standard treatments, which is extremely short compared with that of patients with non-GI cancers (such as breast and prostate cancers),” they explained. “Access to targeted therapies based on genomic profling in patients with GI cancer was reported to be 5%-7% in Japan, which is lower than what has been reported in whole cancer entities.”
The authors conducted a retrospective cohort study to further investigate the utility of genomic profling tests in patients with GI cancers. Their study population consisted of patients with GI cancers and non-GI cancers who underwent tissue-based genomic profling from April 2017 to October 2020 at St. Marianna University School of Medicine Hospital in Japan.
“The profle of gene alterations, frequency of tumor mutational burden-high (TMB-high; ≥ 10 muts/Mb), and accessibility of recommended molecular targeted therapy were compared between patients with GI cancers and patients with non-GI cancers,” said the study authors.
The tissue-based assays used for analysis were Oncomine Comprehensive Assay version 3, FoundationOne CDx, NCC Oncopanel, PleSSision-160, and PleSSision-Exome. A total of 133 patients with GI cancers (most frequent: colorectal, 44%; pancreatic, 20%; gastric, 8%; esophageal, 8%) and 63 patients with non-GI cancers (most frequent: breast, 29%; ovarian, 14%; cervical, 13%; uterine, 8%) were included.
Among patients with GI cancers, genomic profiles showed the highest frequencies of TP53, KRAS, and APC mutations, and a signifcantly lower frequency of PIK3CA mutations compared with non-GI cancers. TMB-high was also found to be significantly less prevalent in GI vs non-GI cancers (4% vs 20%; P = .008).
Based on findings of the tissue-based assays, 29 patients with GI cancers (40%) and 35 patients with non-GI cancers (56%) were recommended for targeted therapies. Of these patients, 7 individuals from each group received the recommended therapy based on their genomic findings, exhibiting similar treatment accessibility between the GI and non-GI cancer groups (10% vs 11%; P = .791).
None of the patients with pancreatic cancer could access any targeted therapies. Human epidermal growth factor receptor 2 (HER2)-targeted and BRAF-targeted therapies were the primary treatments administered to patients with GI cancers.
“Despite their unfavorable genomic profles, patients with GI cancers were able to use targeted therapies similarly to patients with non-GI cancers,” concluded the researchers. “The utility of genomic profling in patients with GI cancers was highlighted to determine their opportunity to receive specific treatments, such as HER2-targeted and BRAF-targeted therapies.”
Reference
Takeda H, Imoto K, Umemoto K, et al. Clinical utility of genomic profling tests in patients with advanced gastrointestinal cancers. Target Oncol. Published online April 2, 2022. doi:10.1007/s11523-022-00871-4
Hospitals Report Declining Cash Reserves, Increasing Reimbursement Delays and Denials
December 1st 2023A new report highlighting the twin pressures hospitals have faced over the last 18 months shows that as reimbursement delays and denials increased and cash and investments decreased, operating expenses have risen sharply.
Read More
Oncology Onward: A Conversation With Thyme Care CEO and Cofounder Robin Shah
October 2nd 2023Robin Shah, CEO of Thyme Care, which he founded in 2020 with Bobby Green, MD, president and chief medical officer, joins hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, to discuss his evolution as an entrepreneur in oncology care innovation and his goal of positively changing how patients experience the cancer system.
Listen
Consumers should not eat precut cantaloupe if they do not know the source, as the number of illnesses and recalls tied to a deadly salmonella outbreak grows; the White House and the Department of Education urged schools to take proactive steps to prevent youth drug use; a study published this week found a high prevalence of arrhythmia in patients with long COVID.
Read More